Discussion
Myeloma UK is calling for more data transparency in government efforts to safeguard myeloma patients during the COVID-19 pandemic. This comes after results…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people…
Discussion
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Discussion
SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents…
Discussion
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma…
Discussion
An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell…
